Fig. 3.

a Platelet, b aspartate aminotransferase (AST), and c alanine aminotransferase (ALT) time courses (fifth and ninety-fifth percentiles) at each time point during the course of trastuzumab emtansine treatment at 3.6 mg/kg every 3 weeks stratified by area under the concentration–time curve (AUC) quartile (Q) in studies TDM3569g, TDM4258g, and TDM4374g. Red bars, 95% confidence intervals; blue circles, patient values below the fifth (platelets) or above the ninety-fifth (AST, ALT) percentile; black dashed line, cutoff for grade 3 or greater adverse event (>5 × upper limit of normal (ULN) for AST and ALT; <50,000 platelet counts)